REGRESSION OF LIVER FIBROSIS IN SCHISTOSOMA MANSONI INFECTED SUDANESE SUBJECTS AFTER PRAZIQUANTEL TREATMENT

  • Siddig A. Rahoud Institute of Nuclear Medicine, Molecular Biology & Oncology, University of Gezira , Wad Medani, Sudan.
  • Adil Mergani Mergani Institute of Nuclear Medicine, Molecular Biology & Oncology, University of Gezira , Wad Medani, Sudan
  • Ammar H. Khamis Khamis Sudan University for Science & Technology, Khartoum, Sudan.
  • Osman K. Saeed Saeed Faculty of Medicine, University of Gezira, Wad Medani, Sudan
  • Qurashi Mohamed-Ali
  • Alain J. Dessein INSERM U399, Immunology & Genetics of Parasitic Diseases / Laboratory Parasitology- Mycology, Faculty of Medicine, Marseile, France.
  • Nasr Eldin M. A. Elwali A. Elwali . Institute of Nuclear Medicine, Molecular Biology & Oncology, University of Gezira , Wad Medani, Sudan

Abstract

Objectives: 1-To evaluate the effect of Praziquantel (PZQ) therapy on the regression of liver fibrosis in an endemic population.


2-To determine the factors controlling the regression of hepatic fibrosis (e.g. gender, age and grade of fibrosis).


 


Material and methods: An association study of a cohort of one hundred seventy seven Sudanese patients infected with Schistosoma mansoni (82 males 46%, 95 females 54%) was conducted to evaluate the factors controlling the regression of liver fibrosis 39 months after treatment with PZQ using ultrasound evaluation. SPSS (Statistical Package for Social Science) software was used for statistical analysis. Chi- Square was used to compare the two phenotypes (regression and progression) in the study subjects.


Results: PPF was regressed in 63 patients (36%) from higher grades of fibrosis to lower ones. While in 24 patients (13 %) the disease progressed to higher grades. In addition, the grade of PPF did not change in 90 patients (51%).  The mean values of portal vein diameter (PVD), splenic vein diameter (SVD), and index liver size (ILS) in subjects in whom PPF regressed after treatment were significantly lower than in subjects in whom the disease was progressed (P < .0001, P = .031, and P = .003 respectively).The progression of hepatic fibrosis in
males (n = 15, 18 %) was greater than that of females (n = 9, 9 %). Patients who showed regression of PPF or progression of the disease tend to cluster in certain families.

References

1. WHO (1993). The control of Schistosomiasi: Second report of the WHO expert committee. Genev, WHO technical report series, 830.
2. WHO/CDS/CPC/SIP/99.2. (1998). Report of the WHO informal consultation on Schistosomiasis control . Geneva.
3. Dessein, A. J.; Hillaire, D.; Elwali, N. M. A.; Marquet, S. ; Mohamed-Ali, Q.; Merghani, A.; Henri, S.; Abdelhameed, A A.; Saeed, O. K.; Magzoub, M. M.A.; and Abel, L. (1999a). Severe hepatic fibrosis in Schistosoma mansoni infection is controled by a major locus that is closely linked to the interferon-γ receptor gene. Am. J. Hum. Genet.65: 709-721.
4. Homeida, M. A.; El Tom, I.A.; Nash, T.; and Bennett, J. L. (1991). Association of the therapeutic activity of praziquantel with the revesal of Symmers fibrosis induced by Schistosoma mansoni . Am. J. Trop.Med. Hyg.45 (3): 360-365.
5. . Kheir, M. M.; Baraka, O. Z.; El Tom, I. A.; Mukhtar, M. M.; and Homieda, M. M. A. (2000). Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis. Easstern Mediterranean Health Journal. 6 (5): 926-931.
6. Mohamed-Ali, Q.; Doehring-Schwerdtfeger, E.; Abdel-Rahim, I. M.; Schlake, J.; Kardorff, R.; Franke, D.; Kaiser, C.; Elsheikh, M.; Abdalla, M.; Schafer, P.; and Ehrich, J. H. H. (1991). Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection : Reversibility of morbidity seven months after treatment with praziquantel . Am. J. Trop. Med. Hyg. 44 (4): 444-451.
7. Doehring-Schwerdtfeger, E.; Abdel-Rahim, I. M. A.; Mohamed-Ali, Q.; Elsheikh, M.; Schlake, J.; Kardroff, R.; Franke, D.; Kiaser, C. H.; and Ehrich, J.H. H. (1990). Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reveraluation of morbidity. Am. J. Trop. Med. Hyg. 42: 581-586.
8. Homeida, M. A.; Eltoum, I. A.; Ali, M. M.; Suliaman, S. M.; Elobied, E.A.; Mansour, M.; Saad, A. M.; and Bennett, J. L . (1996). The effectiveness of annual versus biennial mass hemotherapy in reducing morbidity due to schistosomiasis: A prospective study in Gezira-Managil, Sudan. Am. J. Trop. Med. Hyg. 54 (2): 140-145.
9. Wynn, T. A.; Cheever, A. W.; WilliamsM, E.; Hieny, S.; Caspar, P.; Kuhn, R.; Muller,W.; and Sher, A. (1998). IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J. Immunol. 160: 4473-4480.
10. Wynn, T. A.; Ckeever, A. W.; Jankovic, D.; Poindexter, R.W.; Caspar, P.; Lewis, F. A.; and Sher, A. (1995). An IL-12 based vaccination method for preventing fibrosis induced by Schistosoma infection.Nature.376:594-596.
11. Leptak, C. L.; and McKerrow, J. H. (1997). Schistosome egg granulomas and hepatic expression of TNF-alpha are dependent on immune priming during parasite maturation. J. Immunol.158: 301-307.
12. Cheever, A. W.; Williams, M. E.; Wynn, T. A.; Finkelman, F. D.; Seder, R. A.; Cox, T. M.; Hieny, S.; Caspar, P.; and Sher, A.(1994). Anti-IL-4 treatment of Schistosoma manson infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J. Immunol. 153: 753-759.
13. Czaja, M .J; Weiner, F. R.; Flanders, K. C;Giambrone, M. A.; Wind, R.; Biempica, L.; and Zern, M. A. (1989a). In vitro and in vivo association of transforming growth factor-beta1with hepatic fibrosis.J.Cell. Biol.108: 2477-2482.
14. Czaja, M. J.; Weiner, F. R.; Takahashi, S.; Giambrone, M. A.; Van der Meide, P. H.; Schellekens, H.; Biempica, L.; and Zern, M. A. (1989 b). Gamma-interferon treatment inhibits collagen deposition in murine Schistosomiasis . Hepatology.10: 795-800..


15. Duncan, M.R.; and Berman, B. (1985). Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J. Exp. Med. 162: 516-527.
16. Tamai, K.; Ishikawa, H.; Mauviel, A.; and Uitto, J. (1995). Interferon gamma coordinately upregulates matrix metalloprotease (MMP)-1 and MMP-3 but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. J. Invest. Dermatol. 104: 384-390.
17. Mallat, A.; Preaux, A. M.; Blazejewski, S.; Rosenbaum, J.; Dhumeaux, D.; and Mavier, P. (1995). Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21: 1003-1010.
18. Marquet, S.; Abel, L.; Hillaire, D.; and Dessein, A. J. (1999) Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33.European Journal of Human Genetics.7: 88-97.
19. Dessein, A. J.; Marquet, S.; Henri, S.; El Wali, N. M. A.; Hillaire, D.; Rodrigues, V.; Prata, A.; Mohamed Ali, Q.; Gharib, B.; Reggi, M.; Magzoub, M. M. A.; Saeed,O. K.; Abdelhameed, A. A.; and Abel, L. (1999b).Infection and disease in human S. mansoni are under distinct major gene control. Microbes & infection. 1: 561-567.
20. Henri, S.; Dessei, A. J.; Chevillard, C.; Paris, P.; Godard, J.; Camilla, C.; Saeed, O. K.; Mirgani, A.; Bucheton,B.; Rahoud, S.; Elwali, N. m. A.; Fert, V.; Montero, F.; Mohamed-Ali, Q.; and Magzoub, M. M. A (2002). Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease.J.Immuno.169:929-36.
21. Moukoko, C.E; Elwali, N. m. A.; Saeed, O. K.; Mohamed-Ali, Q.; Gaudart, J.; Dessei, A. J; and Chevillard, C. (2003). No Evidence for a Major Effect of Tumor Necrosis Factor Alpha Gene Polymorphisms in Peripotal Fibrosis Caused by Schistosoma mansoni Infection. Infec. Immunity. 17 (10): 5456 – 5460.
22. Baza H., and Asser L. (1985). HLA antigens in schistosomal hepatic fibrosis with haematemesis. Tissue Antigens, 26: 307-309.
23. Secor, W. E.; del Corral, H.; dos Reis, M. G.; Ramos, E. A.; Zimon, A. E.; and Matos, E. P. (1996). Association of hepatosplenic schistosomiasis with HLA-DQB1*0201. J. Infect. Dis. 174: 1131-5.



24. Katz, N.; chaves, A.; and Pellegrino, J. (1972) A simple device for quantitative stool thick smear technique in Schistosoma mansoni . Rev. Inst. Med. Trop. Sao Paulo. 14: 397-400.
25. Cairo Working Group. (1992). The use of diagnostic ultrasound in schistosomiasis - Attempts at standardization of methodology. Acta. Trop. 51: 54-63.
26. Mohamed-Ali, Q.; Elwali, N. M. A.; Abdelhameed, A. A.; Mergani, A.; Rahoud, S.; Elagib, K.; Saeed, O. K.; Abel, L.; Magzoub, M. M.A.; and Dessein, A. J. (1999) Susceptibility to periportal (Symmers) fibrosis in human Schistosoma mansoni infections: Evidence that intensity and duration of infection, gender, and inherited factors are critical in disease progression. J. Infec. Dis. 180: 1298-1306.
27. Dittrich, M.; Milde, S.; Dinkel, E.; Baumann, W.; and Weitzel, D. (1983). Sonographic biometry of liver and spleen size in childhood. Pediatr. Radiol. 13:205-211.
28. Abdel-Wahab, M. F.; Esmat, G.; Milad, M.; Abdel-Razek, S.; and Strickland, G. T. (1989). Characteristic sonographic pattern of schistosomal hepatic fibrosis. Am. J. Trop. Med. Hyg.40: 72-76.
29. Kilpatrick, M. E.; Farid, Z.; Bassily, S.; El-Masry, N. A.; Trabolsi, B.; and Watten, R. H. (1981). Treatment of schistosomiasis with Oxamniquine. Am. J. Trop. Med. Hyg. 30: 1219-1222.
30. .Sleigh, A. C.; Mott, K.E.; Hoff, R.; et al. (1985). Three-year prospective study of the evaluation of mansoni schistosomiasis in northeast Brazil. Lancet 2: 63-66.
31. Utzinger, J.; N´Goran, E.K.; N´Dri, A.; Lengeler, C.; and Tanner, M.(2000).Efficacy of Praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop. Med. Int. Health 5:771-778.
32. Garba, A.; Tohon, Z.; Sidiki, A.; Chippaux, J.P.; and de Chabalier, F.(2001).Efficacity of praziquantel in school-aged children in a hyperendemic zone for Schistosoma haematobium (Niger,1999). Bull. Soc. Pathol. Exot. 94:42-45.
33. Pellegrino J.; and Katz, N. (1968). Experimental chemotherapy of schistosomiasis mansoni. Adv. Parasitol. 6: 233-290.
34. Cavalcanti, A.;,Barbosa, J. R.; Arvon, A.; and Andrade, Z. A. (2002). Contribution to the study of collagen degradation. J. Bras. Patol. Med. Lab. 38:(4) 325-332.

35. Xu, J.W.; Gong, J.; Chang, X. M.; Luo, J. Y.; Dong, L.; Hao, Z. M.; Jia, A.; and Xu, G. P. (2002). Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol.8:(5)883-887.
36. Colborn,T.; vom ,S.F.S.; and Soto, A.M. (1993). Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect. 101::378–384.
Published
2005-01-01
How to Cite
RAHOUD, Siddig A. et al. REGRESSION OF LIVER FIBROSIS IN SCHISTOSOMA MANSONI INFECTED SUDANESE SUBJECTS AFTER PRAZIQUANTEL TREATMENT. Gezira Journal of Health Sciences, [S.l.], v. 1, n. 2, jan. 2005. ISSN 1810-5386. Available at: <http://journals.uofg.edu.sd/index.php/gjhs/article/view/173>. Date accessed: 26 aug. 2019.
Section
Articles